MAM
MNPR icon

Meeder Asset Management’s Monopar Therapeutics MNPR Stock Holding History

Meeder Asset Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$129K Buy
1,389
+752
+118% +$46.6K 0.01% 342
2026
Q1 		$34.9K Sell
637
-357
-36% -$21.6K ﹤0.01% 493
2025
Q4 		$64.9K Buy
+994
New +$81.2K ﹤0.01% 372

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Meeder Asset Management's MNPR Position: Q2 2026 in Review

Meeder Asset Management increased its Monopar Therapeutics (MNPR) stake by 118% in Q2 2026, buying an estimated $46.6K and bringing the position to 1,389 shares worth $129K. The position accounts for 0.01% of the portfolio, ranked #342.

Meeder Asset Management first reported a position in MNPR in Q4 2025 and has held it in 3 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Meeder Asset Management held 1,389 shares of Monopar Therapeutics worth $129K as of Q2 2026.
  • Meeder Asset Management bought 752 Monopar Therapeutics shares in Q2 2026, an estimated $46.6K.
  • Monopar Therapeutics made up 0.01% of Meeder Asset Management's portfolio in Q2 2026, its #342 holding.
  • Meeder Asset Management first reported a position in Monopar Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.